02:50 PM EDT, 03/18/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We reduce our 12-month target price to $193 from $227, 14.6x our 2026 EPS of $13.20 (unchanged), below IQV's five-year historical forward P/E average of 21.6x. We trim our 2025 estimate to $11.95 from $12.04 as we are reducing our revenue growth forecast for this year. Despite the sell-off in IQV's shares in the last month (-3.83% M/M), we continue to see limited upside potential at current valuations given the challenging business environment the firm is navigating. While we see IQV as a differentiated and well diversified player, we think its sales and profitability may continue to be pressured, due to a challenging global macroeconomic backdrop. Despite our expectations for a gradual recovery Q/Q, we view 2025 as a challenging year due to continued spending caution and budgetary discipline from large pharma clients. We now see top-line sales growth of 3.2% Y/Y in 2025 versus 4.6% Y/Y earlier, as we expect slower growth in the first half of the year.